Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
NCT03217838 · AstraZeneca · PHASE1 · terminated · last registry update 2022-04-05 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “strategic decision” | Open Targets' class: business administrative | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BCL2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-01-27Results posted on the registry: AbbVie, Azacitidine + Venetoclax (NCT02993523)
- 2022-12-16Phase 3 first posted: The First Affiliated Hospital of Soochow University, Azacitidine Combined With Venetoclax and ATRA group (NCT05654194)
- 2022-01-10Phase 3 first posted: PedAL BCU, LLC, Fludarabine + Cytarabine (NCT05183035)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision